Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Hülsmeyer

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
The Journal of Biological Chemistry|November 13, 2004
A major histocompatibility complex-peptide-restricted antibody and t cell receptor molecules recognize their target by distinct binding modes: crystal structure of human leukocyte antigen (HLA)-A1-MAGE-A1 in complex with FAB-HYB3Martin Hülsmeyer, Patrick Chames, Roman C Hillig, et al.
Molecular Cancer Therapeutics|September 5, 2013
A highly potent and specific MET therapeutic protein antagonist with both ligand-dependent and ligand-independent activityShane A Olwill, Christian Joffroy, Hendrik Gille, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 12, 2014
In vivo visualization of MET tumor expression and anticalin biodistribution with the MET-specific anticalin 89Zr-PRS-110 PET tracerAnton G T Terwisscha van Scheltinga, Marjolijn N Lub-de Hooge, Marlon J Hinner, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
The Journal of Biological Chemistry|November 13, 2004
A major histocompatibility complex-peptide-restricted antibody and t cell receptor molecules recognize their target by distinct binding modes: crystal structure of human leukocyte antigen (HLA)-A1-MAGE-A1 in complex with FAB-HYB3Martin Hülsmeyer, Patrick Chames, Roman C Hillig, et al.
Molecular Cancer Therapeutics|September 5, 2013
A highly potent and specific MET therapeutic protein antagonist with both ligand-dependent and ligand-independent activityShane A Olwill, Christian Joffroy, Hendrik Gille, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 12, 2014
In vivo visualization of MET tumor expression and anticalin biodistribution with the MET-specific anticalin 89Zr-PRS-110 PET tracerAnton G T Terwisscha van Scheltinga, Marjolijn N Lub-de Hooge, Marlon J Hinner, et al.
Pageof 2